Commented Owen Roberts.

We’re very pleased with the self-confidence and support proven by our investors to summarize this financing circular and delighted to really have the OETF join us, commented Owen Roberts, Chief Financial Officer of Affinium Pharmaceuticals. This funding will completely fund Affinium’s next two key development goals, the completion of a phase 2 trial for our oral tablet and stage 1 trials of our new IV formulations stated Dr.The decrease is due primarily to lessen net expenditure income and is in keeping with the run-off character of the segment. Net income of $5.5 million for the initial quarter of 2011, weighed against net gain of $15.0 million for the initial quarter of 2010. Total company results Revenues were $8.3 billion for the first quarter of 2011 compared with $8.5 billion for the first quarter of 2010. This decrease was mainly the consequence of a decline in Health Care premium revenue primarily caused by lower Commercial Insured membership in 2011, in addition to a decline from adjustments in the client market, item and geographic mix of business, partially offset by superior rate boosts.